Grail in Minimum Residual Disease Collaborations With Amgen, AstraZeneca, Bristol Myers
11 Januar 2021 - 7:55PM
Dow Jones News
By Colin Kellaher
Cancer-testing company Grail Inc. on Monday said it formed
collaborations with Amgen Inc., AstraZeneca PLC and Bristol Myers
Squibb Co. to study Grail's technology for the detection of the
small number of cancer cells left in the body after treatment,
known as minimal residual disease.
Grail, which has developed a blood test aimed at the early
detection of dozens of cancers, said it will work with the
biopharmaceutical giants to evaluate the benefits of using its
technology to find minimal residual disease after treatment or to
detect early recurrent cancers.
Grail said its targeted methylation platform could enable a
blood-based minimal residual disease detection assay for solid
tumors that perform comparably to currently available tissue-based
assays, while reducing complexity and processing times.
Gene-sequencing company Illumina Inc., which spun out Grail in
2016 and still owns about 14.6% of the company, in September said
it would pay about $7.1 billion in cash and stock to acquire the
rest of the company in a deal expected to close later this
year.
Grail separately said it expects to introduce its multi-cancer
early detection blood test, dubbed Galleri, in the second
quarter.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 11, 2021 13:40 ET (18:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024